logo-loader
viewTRACON Pharmaceuticals

Full interview: TRACON Pharmaceuticals reveals platform milestones and most recent pipeline update

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer updated Proactive on the San Diego-based company's platform milestones and most recent pipeline update including its therapy licensed from a company in China to treat sarcoma.

Theuer says the company plans to meet with the FDA in Q2 of this year, file an Investigational New Drug application to potentially begin a pivotal study in Q2, apply for and gain Orphan Drug Designation, and dose a pivotal trial in Q3.

Quick facts: TRACON Pharmaceuticals

Price: 1.69 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $9.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: TRACON Pharmaceuticals brings on biotech veteran to its...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive the San Diego-based biotech has named Saundra Pelletier, who currently heads up Evofem Biosciences Inc (NASDAQ:EVFM), as a new board director. Theuer says Pelletier is currently leading that firm's effort to bring...

2 weeks, 5 days ago

2 min read